Loading…
Senores Pharmaceuticals (SENORES)₹1,175−1.59%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Senores Pharmaceuticals reported sales of ₹192 Cr, up 18.6% from Sep 2025, and net profit of ₹36.93 Cr, up 23.4% year on year. For the year to Mar 2026, sales were ₹632 Cr and net profit ₹122 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 78.85 | 102 | 79.80 | 101 | 103 | 114 | 138 | 162 | 171 | 175 | 180 | 192 |
| Expenses | 63.75 | 79.68 | 58.78 | 76.68 | 76.65 | 94.69 | 104 | 112 | 120 | 128 | 126 | 135 |
| Operating Profit | 15.01 | 22.01 | 21.01 | 23.01 | 25.99 | 19.01 | 34.01 | 49.98 | 49.98 | 46.97 | 53.98 | 58.02 |
| OPM % | 19.1% | 22.0% | 27.1% | 23.1% | 25.1% | 17.1% | 25.1% | 31.1% | 29.1% | 27.1% | 30.1% | 30.1% |
| Other Income | 1.01 | 2.01 | 0.00 | 2.01 | 5.02 | 12.03 | 3.01 | 5.01 | 7.02 | 18.05 | 3.01 | 9.02 |
| Interest | 2.01 | 3.01 | 5.01 | 5.02 | 6.02 | 5.02 | 5.01 | 6.02 | 5.02 | 8.03 | 7.02 | 9.03 |
| Depreciation | 2.99 | 3.98 | 3.99 | 3.99 | 3.99 | 4.98 | 5.97 | 7.97 | 7.98 | 8.97 | 9.97 | 9.97 |
| Profit before tax | 9.98 | 17.94 | 12.96 | 15.95 | 19.95 | 20.93 | 25.92 | 40.87 | 44.86 | 46.87 | 38.92 | 47.85 |
| Tax % | 31.1% | 19.0% | 19.1% | 18.0% | 20.0% | 13.1% | 20.0% | 26.0% | 25.1% | 23.1% | 23.0% | 23.0% |
| Net Profit | 6.99 | 13.98 | 10.97 | 12.97 | 15.96 | 17.95 | 20.96 | 29.92 | 33.93 | 36.94 | 29.92 | 36.93 |
| EPS (Rs) | 2.36 | 5.22 | 3.22 | 3.85 | 3.72 | 3.86 | 4.27 | 7.02 | 6.86 | 6.84 | 6.66 | 8.55 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales | 13.96 | 34.92 | 214 | 397 | 632 | 717 |
| Expenses | 11.95 | 22.92 | 172 | 308 | 462 | 508 |
| Operating Profit | 2.01 | 13.01 | 42.03 | 90.01 | 168 | 209 |
| OPM % | 14.1% | 36.1% | 19.0% | 23.1% | 27.1% | 29.2% |
| Other Income | 0.00 | 4.01 | 3.01 | 19.05 | 47.12 | 37.10 |
| Interest | 1.01 | 2.01 | 9.03 | 22.07 | 25.08 | 29.10 |
| Depreciation | 0.99 | 1.99 | 9.96 | 16.93 | 30.90 | 36.89 |
| Profit before tax | 0.99 | 11.96 | 24.92 | 70.76 | 159 | 179 |
| Tax % | 13.1% | 32.0% | −31.0% | 17.1% | 24.1% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 0.99 | 7.98 | 32.95 | 57.85 | 122 | 138 |
| EPS (Rs) | 1.00 | 8.57 | 10.28 | 12.69 | 24.99 | 28.91 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 9.01 | 10.00 | 31.04 | 46.06 | 46.06 |
| Reserves | 27.96 | 35.95 | 174 | 739 | 886 |
| Borrowings | 15.01 | 63.00 | 258 | 316 | 342 |
| Other Liabilities | 7.95 | 22.89 | 160 | 126 | 329 |
| Total Liabilities | 58.93 | 131 | 622 | 1,227 | 1,604 |
| Fixed Assets | 6.98 | 26.95 | 234 | 300 | 753 |
| CWIP | 7.98 | 33.91 | 96.85 | 172 | 16.97 |
| Investments | 14.94 | 15.94 | 0.00 | 0.00 | 3.99 |
| Other Assets | 29.03 | 53.04 | 289 | 755 | 829 |
| Inventories | 3.01 | 3.01 | 37.06 | 57.10 | 89.28 |
| Trade receivables | 19.95 | 21.95 | 112 | 124 | 324 |
| Cash & equivalents | 3.01 | 0.00 | 13.01 | 387 | 160 |
| Total Assets | 58.93 | 131 | 622 | 1,227 | 1,604 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | −9.96 | −0.99 | −25.92 | −45.84 | 61.82 |
| Cash from investing activity | −24.06 | −48.15 | −54.14 | −430 | −121 |
| Cash from financing activity | 35.94 | 45.94 | 86.91 | 573 | −0.99 |
| Net cash flow | 1.99 | −2.99 | 7.98 | 97.67 | −59.86 |
| Capex | 10.98 | 46.95 | 51.90 | 158 | 264 |
| Free cash flow | −21.02 | −48.07 | −78.08 | −203 | −203 |
| CFO / OP % | −526.1% | 3.0% | −56.1% | −41.1% | 44.9% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 506 | 228 | 191 | 114 | 187 |
| Inventory days | 134 | 88 | 183 | 231 | 129 |
| Days payable | 324 | 388 | 556 | 275 | 340 |
| Cash conversion cycle | 317 | −71 | −182 | 70 | −24 |
| Working capital days | 360 | −6 | −15 | 89 | 133 |
| ROCE % | — | 18.0% | 12.1% | 11.0% | 15.0% |
For the Sep 2026 quarter, Senores Pharmaceuticals reported sales of ₹192 Cr, up 18.6% year on year and net profit of ₹36.93 Cr, up 23.4% year on year. The operating margin was 30.1%.
Senores Pharmaceuticals' sales for the year to Mar 2026 were ₹632 Cr; over the last twelve months they were ₹717 Cr.
Net profit for the year to Mar 2026 was ₹122 Cr, and ₹138 Cr over the last twelve months. Earnings per share over the same trailing period were ₹28.91.
Senores Pharmaceuticals reported borrowings of ₹342 Cr at Mar 2026, against cash and equivalents of ₹160 Cr.
Cash from operations was ₹61.82 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹203 Cr.